已收盘 03-18 16:00:00 美东时间
0.000
0.00%
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in the third quarter of 2024, ahead of the broader S&P 500 index which rose 5.25...
10-02 22:07
市场预计,Cobenfy 2028年销售额可达28亿美元,峰值销售额将达到约60亿美元。 全球首款精神分裂症新药在美获批,2028年销售额可能高达28亿美元。...
09-27 21:56
FDA周四批准了由美国医药巨头百时美施贵宝公司开发的Cobenfy(xanomeline以及trospium chloride),作为治疗精神分裂症成人患者的最新疗法。
09-27 20:55
KarXT在美获批,也为中国患者带来希望。 当地时间9月26日,美国食品药品监督管理局(FDA)宣布批准百时美施贵宝(BMS)公司精神分裂药物Cobe...
09-27 19:33
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could offer insights into the health of the U.S....
09-27 17:25
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that KarXT
09-27 14:39
2024年9月26日,百时美施贵宝(BMS)同类首创新药Cobenfy (xanomeline和trospium chloride复方,KarXT)顺利获得F...
09-27 13:37
近日,FDA宣布批准百时美施贵宝的口服创新复方制剂Cobenfy (KarXT)用于治疗精神分裂症成人患者。 一直以来,精神病的新药开发是出了名的困难,存在巨大...
09-27 12:01
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by Bristol-Myers Squibb (NYSE:BMY), as a novel treatment for adults with the psyc...
09-27 08:36